Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merck 4Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Merck 4Q

Singulair sales were $1.1 billion in the quarter (-3%) and $4.3 billion for the year (+2%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck

4Q Revenues: $6.0 billion (-3%)

4Q Earnings: $1.6 billion (loss of $1.6 billion in 4Q07)

FY Revenues: $23.9 billion (-1%)

FY Earnings: $7.8 billion (earnings were $3.3 billion FY07)

Comments: Singulair sales were $1.1 billion in the quarter (-3%) and $4.3 billion for the year (+2%). Cozaar and Hyzaar sales were $881 million in the quarter (-1%) and $3.6 billion for the year (+6%). Fosamax and Fosamax Plus D sales were $318 million in the quarter (-60%) and $1.6 billion for the year (-49%), due to loss of marketing exclusivity. Gardasil sales were $286 million in the quarter (-16%) and $1.4 billion for the year (-5%). Januvia sales were $413 million in the quarter (+64%) and $1.4 billion for the year. Janumet sales were $120 million in the quarter compared to $44 million in 4Q07 and reached $351 million for the year. Isentress sales were $130 million for the quarter and $361 million for the year.

Combined global sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough partnership, were $1.1 billion in the quarter (-26%) and $4.6 billion for the year (-12%). Restructuring costs were $33 million in the quarter and $123 million for the year. R&D expenses were flat at $1.4 billion in the quarter and $4.8 billion for the year (-2%). For the year, earnings include a $2.2 billion pretax gain on distribution from AstraZeneca. Results in 2007 reflect a $4.9 billion pretax charge related to the U.S. Vioxx Settlement Agreement. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters